Argent Capital Management Lowered Biogen (BIIB) Stake by $13.09 Million; Bridgewater …

Bridgewater Associates Lp decreased its stake in Open Text Corp (OTEX) by 13.78% based on its latest 2018Q4 regulatory filing with the SEC.

Open Text Corporation (NASDAQ:OTEX) Logo

Argent Capital Management Llc decreased its stake in Biogen Inc. (BIIB) by 33.36% based on its latest 2018Q4 regulatory filing with the SEC. Argent Capital Management Llc sold 43,636 shares as the company’s stock declined 1.50% while stock markets rallied. The institutional investor held 87,154 shares of the biological products (no diagnostic substances) company at the end of 2018Q4, valued at $26.23M, down from 130,790 at the end of the previous reported quarter. Argent Capital Management Llc who had been investing in Biogen Inc. for a number of months, seems to be less bullish one the $44.19 billion market cap company. The stock decreased 3.46% or $8.16 during the last trading session, reaching $227.91. About 1.69 million shares traded. Biogen Inc. (NASDAQ:BIIB) has risen 15.91% since May 7, 2018 and is uptrending. It has outperformed by 11.54% the S&P500. Some Historical BIIB News: 24/04/2018 – Biogen Idec 1Q Adj EPS $6.05; 07/03/2018 – EMA- EMA RECOMMENDS IMMEDIATE SUSPENSION AND RECALL OF MULTIPLE SCLEROSIS MEDICINE ZINBRYTA; 25/04/2018 – BIOGEN INC BIIB.O : BAIRD RAISES TO OUTPERFORM; 24/04/2018 – BIOGEN 1Q TECFIDERA REV. $986.9M, EST. $1.01B; 06/03/2018 – PROMIS NEUROSCIENCES INC – PMN310 SHOWED SIMILAR ABILITY TO CROSS BLOOD BRAIN BARRIER AND PENETRATE CENTRAL NERVOUS SYSTEM COMPARED TO ADUCANUMAB; 23/04/2018 – BIOGEN: NEW SPINRAZA DATA UNVEILED AT AAN ANNUAL MEETING SHOW; 17/05/2018 – BIOGEN TO EXERCISE CALL OPTIONS ON SAMSUNG BIOEPIS BY JUNE 29; 24/04/2018 – Biogen’s rain-making rare-disease drug hits a sales slump; 07/05/2018 – Eaton Vance Worldwide Health Adds Glaxo, Cuts Biogen; 01/05/2018 – Biogen Will Pay $50 Million To Reduce Royalties On Alzheimer’s Disease Drug — MarketWatch

Bridgewater Associates Lp decreased its stake in Open Text Corp (OTEX) by 13.78% based on its latest 2018Q4 regulatory filing with the SEC. Bridgewater Associates Lp sold 13,350 shares as the company’s stock rose 9.45% with the market. The hedge fund held 83,536 shares of the edp services company at the end of 2018Q4, valued at $2.72M, down from 96,886 at the end of the previous reported quarter. Bridgewater Associates Lp who had been investing in Open Text Corp for a number of months, seems to be less bullish one the $10.61 billion market cap company. The stock decreased 1.77% or $0.71 during the last trading session, reaching $39.49. About 211,788 shares traded. Open Text Corporation (NASDAQ:OTEX) has risen 9.17% since May 7, 2018 and is uptrending. It has outperformed by 4.80% the S&P500. Some Historical OTEX News: 02/04/2018 MADHU RANGANATHAN JOINS OPENTEXT AS CHIEF FINANCIAL OFFICER; 10/05/2018 – OPEN TEXT CORP OTEX.TO : BARCLAYS RAISES TARGET PRICE TO C$59 FROM C$57; 30/05/2018 – OPEN TEXT -AMENDMENT OF TERM LOAN INCREASES AMOUNT TO US$1 BLN, EXTENDS MATURITY DATE TO 2025, REDUCES INTEREST RATE MARGIN BY 25 BASIS POINTS; 17/04/2018 – Open Text Closes Above 50-Day Moving Average: Technicals; 18/05/2018 – Document Management Software 2018: Global Procurement Market Intelligence Report – Top Five Players are Adobe, OpenText, Dropbox, HP, and Oracle – ResearchAndMarkets.com; 17/04/2018 – BLUE HARBOUR GROUP LP CEO CLIFF ROBBINS TELLS 13D MONITOR CONFERENCE THAT THERE IS “POTENTIAL FOR A STRATEGIC SALE DOWN THE ROAD” FOR OPEN TEXT CORP OTEX.TO , IN WHICH BLUE HARBOUR OWNS 4 PCT STAKE; 09/05/2018 – Open Text 3Q Net $58.8M; 30/05/2018 – OPENTEXT ANNOUNCES REPRICING AND AMENDMENT OF CREDIT FACILITIES; 15/05/2018 – OpenText to Bring Security to the Edges of the Network and Beyond; 30/05/2018 – OPENTEXT TERM LOAN INCREASED TO $1B, MATURITY DATE TO 2025

Analysts await Open Text Corporation (NASDAQ:OTEX) to report earnings on May, 8. They expect $0.08 earnings per share, down 63.64% or $0.14 from last year’s $0.22 per share. OTEX’s profit will be $21.49M for 123.41 P/E if the $0.08 EPS becomes a reality. After $0.39 actual earnings per share reported by Open Text Corporation for the previous quarter, Wall Street now forecasts -79.49% negative EPS growth.

Bridgewater Associates Lp, which manages about $10.93 billion US Long portfolio, upped its stake in Block H & R Inc (NYSE:HRB) by 22,445 shares to 33,567 shares, valued at $852,000 in 2018Q4, according to the filing. It also increased its holding in Las Vegas Sands Corp (NYSE:LVS) by 91,866 shares in the quarter, for a total of 119,032 shares, and has risen its stake in Ford Mtr Co Del (NYSE:F).

More notable recent Open Text Corporation (NASDAQ:OTEX) news were published by: Seekingalpha.com which released: “Open Text Acquires Catalyst Repository Systems For eDiscovery Tech – Seeking Alpha” on February 06, 2019, also Seekingalpha.com with their article: “Open Text Corporation (OTEX) CEO Mark Barrenechea on Q2 2019 Results – Earnings Call Transcript – Seeking Alpha” published on January 31, 2019, Fool.com published: “OpenText Looks to Acquisitions for Growth – Motley Fool” on February 01, 2019. More interesting news about Open Text Corporation (NASDAQ:OTEX) were released by: Nasdaq.com and their article: “After-Hours Earnings Report for January 31, 2019 : AMZN, AFL, EW, MCK, YUMC, AJG, SYMC, EMN, PKI, OTEX, CPT, FBHS – Nasdaq” published on January 31, 2019 as well as Prnewswire.com‘s news article titled: “OpenText Releases New Cloud and Hybrid Offerings for SAP® Solutions – PRNewswire” with publication date: May 03, 2019.

Since January 30, 2019, it had 2 buys, and 0 insider sales for $47.78 million activity.

Investors sentiment decreased to 0.91 in Q4 2018. Its down 0.10, from 1.01 in 2018Q3. It worsened, as 79 investors sold BIIB shares while 314 reduced holdings. 83 funds opened positions while 276 raised stakes. 181.17 million shares or 8.34% more from 167.21 million shares in 2018Q3 were reported. Ingalls And Snyder Limited Co, a New York-based fund reported 7,437 shares. Country Tru Financial Bank reported 112,718 shares or 1.69% of all its holdings. 3,074 were accumulated by Walleye Trading Limited Liability. 2,118 are owned by Heritage Wealth Advsr. Toronto Dominion Savings Bank reported 0.06% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Covington Capital has invested 0% of its portfolio in Biogen Inc. (NASDAQ:BIIB). D E Shaw And accumulated 397,153 shares. Teachers Retirement Sys Of The State Of Kentucky has invested 0.44% in Biogen Inc. (NASDAQ:BIIB). Bamco Ny reported 0.02% in Biogen Inc. (NASDAQ:BIIB). Stevens Cap Mgmt Ltd Partnership invested 0.02% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Nordea Investment Ab owns 425,614 shares. 3,891 are owned by Buckingham Capital Mngmt. Parnassus Invests Ca has invested 0.46% in Biogen Inc. (NASDAQ:BIIB). Cibc World Mkts Corporation has invested 0.19% in Biogen Inc. (NASDAQ:BIIB). Moreover, Culbertson A N Co Inc has 0.08% invested in Biogen Inc. (NASDAQ:BIIB).

Biogen Inc. (NASDAQ:BIIB) Ratings Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

Rowland & Company Investment Counsel Has Upped Microsoft (MSFT) Position By $172.97 …

… 3Q Rev $26.8B; 04/04/2018 – ECS Achieves AWS Microsoft Workloads Competency Status; 21/05/2018 – Microsoft has bought Semantic Machines, …

Biogen Inc. (NASDAQ:BIIB) Logo

Rowland & Company Investment Counsel increased Microsoft Corp (MSFT) stake by 2.63% reported in 2018Q4 SEC filing. Rowland & Company Investment Counsel acquired 1,703 shares as Microsoft Corp (MSFT)’s stock rose 1.03%. The Rowland & Company Investment Counsel holds 66,376 shares with $6.74 billion value, up from 64,673 last quarter. Microsoft Corp now has $968.54 billion valuation. The stock decreased 1.16% or $1.49 during the last trading session, reaching $126.39. About 16.06M shares traded. Microsoft Corporation (NASDAQ:MSFT) has risen 20.90% since May 2, 2018 and is uptrending. It has outperformed by 16.53% the S&P500. Some Historical MSFT News: 13/03/2018 – CafeX Extends CRMs Power with New Release of Live Assist for Microsoft Dynamics 365; 02/05/2018 – Oath also uses certain cloud services from Google and Microsoft; 26/04/2018 – MICROSOFT – QTRLY DILUTED EARNINGS PER SHARE WAS $0.95 AND INCREASED 36%; 27/04/2018 – The “Mad Money” host says Microsoft and Intel could rule the world again; 30/04/2018 – Partnership with Microsoft will bring computer science to four El Paso schools; 26/04/2018 – Microsoft 3Q Rev $26.8B; 04/04/2018 – ECS Achieves AWS Microsoft Workloads Competency Status; 21/05/2018 – Microsoft has bought Semantic Machines, an artificial intelligence start-up that adds context to conversations and improves speech recognition with chatbots; 30/04/2018 – VMWARE: MICROSOFT AZURE NEXT PARTNER FOR VMW’S NETWORKING CLOUD; 15/05/2018 – Bluecrest Adds Lockheed, Exits Altria, Cuts Microsoft: 13F

Willingdon Wealth Management increased Biogen Inc (BIIB) stake by 2923.08% reported in 2018Q4 SEC filing. Willingdon Wealth Management acquired 3,800 shares as Biogen Inc (BIIB)’s stock declined 1.50%. The Willingdon Wealth Management holds 3,930 shares with $1.18 million value, up from 130 last quarter. Biogen Inc now has $44.77B valuation. The stock increased 0.61% or $1.41 during the last trading session, reaching $230.91. About 1.05 million shares traded. Biogen Inc. (NASDAQ:BIIB) has risen 15.91% since May 2, 2018 and is uptrending. It has outperformed by 11.54% the S&P500. Some Historical BIIB News: 23/04/2018 – Biogen: Later-Onset Spinal Muscular Atrophy Patients Treated With Spinraza Walked Longer Distances While Experiencing Stable or Less Fatigue Over Time; 05/04/2018 – Biogen To Launch Imraldi in Europe on October 16; 20/04/2018 – DJ Biogen Inc, Inst Holders, 1Q 2018 (BIIB); 11/04/2018 – moneycontrol: In exclusive pact, Eisai to distribute Biogen’s multiple-sclerosis portfolio in India; 27/04/2018 – Biogen Closes Above 50-Day Moving Average: Technicals; 23/04/2018 – Biogen’s Tecfidera Falls After 1-Wk Rise, Avonex Declines: MS; 11/04/2018 – STAT Plus: Biogen and the badly needed gene therapy acquisition that got away; 01/05/2018 – BIIB TO MAKE 1-TIME $50M PAYMENT TO NEURIMMUNE FOR 5% REDUCTION; 30/05/2018 – STAT Plus: Pharmalittle: Biogen escapes a compulsory license; could Ambien cause racist tweeting?; 14/03/2018 – Rydex Biotechnology Cuts Biogen

Since November 5, 2018, it had 0 insider purchases, and 6 sales for $34.60 million activity. Nadella Satya had sold 267,466 shares worth $28.35 million on Wednesday, February 6. Capossela Christopher C also sold $422,000 worth of Microsoft Corporation (NASDAQ:MSFT) shares. Shares for $214,363 were sold by BROD FRANK H. $4.06 million worth of Microsoft Corporation (NASDAQ:MSFT) shares were sold by Hogan Kathleen T.

Investors sentiment increased to 0.94 in Q4 2018. Its up 0.13, from 0.81 in 2018Q3. It is positive, as 55 investors sold MSFT shares while 925 reduced holdings. 168 funds opened positions while 758 raised stakes. 5.48 billion shares or 3.82% more from 5.28 billion shares in 2018Q3 were reported. Jag Cap Mngmt Ltd Llc holds 3.22% of its portfolio in Microsoft Corporation (NASDAQ:MSFT) for 172,071 shares. Jcic Asset Mgmt Inc holds 1.74% in Microsoft Corporation (NASDAQ:MSFT) or 38,696 shares. Advisory Ser reported 0.49% of its portfolio in Microsoft Corporation (NASDAQ:MSFT). 34,449 are owned by Sol Cap Management Com. Chilton Management Limited Liability Corp reported 272,895 shares. Boys Arnold & Co Incorporated has 56,652 shares. Edge Wealth Management Llc holds 145,069 shares or 4.15% of its portfolio. Somerset Tru holds 83,950 shares or 4.96% of its portfolio. Jpmorgan Chase Communications invested in 88.59M shares or 2.08% of the stock. Janney Limited Liability Company stated it has 2.12% in Microsoft Corporation (NASDAQ:MSFT). Natixis has invested 2.87% in Microsoft Corporation (NASDAQ:MSFT). Appleton Prtnrs Ma invested in 106,962 shares. 496,202 are held by Oakmont Corporation. Moreover, Hemenway Com Ltd Limited Liability Company has 2.69% invested in Microsoft Corporation (NASDAQ:MSFT). 5.84M were accumulated by Proshare Advsr Ltd Liability.

More notable recent Microsoft Corporation (NASDAQ:MSFT) news were published by: Seekingalpha.com which released: “Microsoft: Suprisingly Steady Growth – Seeking Alpha” on May 02, 2019, also Seekingalpha.com with their article: “Microsoft’s Strong Results May Push Shares Even Higher – Seeking Alpha” published on May 01, 2019, Nasdaq.com published: “Microsoft (MSFT) 3rd Quarter Earnings: What to Expect – Nasdaq” on April 24, 2019. More interesting news about Microsoft Corporation (NASDAQ:MSFT) were released by: Nasdaq.com and their article: “Factors to Consider Ahead of Microsoft’s (MSFT) Q3 Earnings – Nasdaq” published on April 22, 2019 as well as Nasdaq.com‘s news article titled: “Technology Sector Update for 05/02/2019: ZNGA, CDAY, SQ, MSFT, AAPL, IBM, CSCO, GOOG – Nasdaq” with publication date: May 02, 2019.

Among 12 analysts covering Microsoft (NASDAQ:MSFT), 12 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Microsoft had 19 analyst reports since November 26, 2018 according to SRatingsIntel. The stock has “Buy” rating by UBS on Thursday, April 25. The rating was maintained by Morgan Stanley with “Overweight” on Thursday, April 25. The stock has “Overweight” rating by Barclays Capital on Thursday, April 25. The stock of Microsoft Corporation (NASDAQ:MSFT) earned “Overweight” rating by Barclays Capital on Friday, April 12. On Thursday, November 29 the stock rating was maintained by Wedbush with “Buy”. The rating was maintained by Deutsche Bank on Monday, November 26 with “Buy”. RBC Capital Markets maintained it with “Buy” rating and $130 target in Monday, March 25 report. Nomura maintained Microsoft Corporation (NASDAQ:MSFT) on Thursday, April 25 with “Buy” rating. The rating was maintained by KeyBanc Capital Markets on Thursday, April 25 with “Overweight”. The stock of Microsoft Corporation (NASDAQ:MSFT) has “Overweight” rating given on Wednesday, April 17 by KeyBanc Capital Markets.

Rowland & Company Investment Counsel decreased Lilly Eli & Co (NYSE:LLY) stake by 215 shares to 39,033 valued at $4.52B in 2018Q4. It also reduced Clorox Company (NYSE:CLX) stake by 811 shares and now owns 2,378 shares. Weyerhaeuser Co Reit (NYSE:WY) was reduced too.

Among 18 analysts covering Biogen (NASDAQ:BIIB), 8 have Buy rating, 0 Sell and 10 Hold. Therefore 44% are positive. Biogen had 37 analyst reports since December 19, 2018 according to SRatingsIntel. The stock of Biogen Inc. (NASDAQ:BIIB) has “Buy” rating given on Thursday, March 21 by Piper Jaffray. The stock of Biogen Inc. (NASDAQ:BIIB) has “Hold” rating given on Thursday, March 21 by Goldman Sachs. Mizuho maintained it with “Buy” rating and $416 target in Wednesday, March 20 report. The stock of Biogen Inc. (NASDAQ:BIIB) has “Buy” rating given on Thursday, March 21 by Cantor Fitzgerald. Canaccord Genuity downgraded Biogen Inc. (NASDAQ:BIIB) on Thursday, March 21 to “Hold” rating. The stock of Biogen Inc. (NASDAQ:BIIB) has “Buy” rating given on Monday, March 25 by H.C. Wainwright. As per Monday, March 4, the company rating was maintained by Cowen & Co. Cantor Fitzgerald maintained it with “Buy” rating and $400 target in Monday, March 4 report. The firm earned “Hold” rating on Thursday, March 21 by Stifel Nicolaus. As per Wednesday, December 19, the company rating was maintained by Morgan Stanley.

More notable recent Biogen Inc. (NASDAQ:BIIB) news were published by: Finance.Yahoo.com which released: “What Do Analysts Think About Biogen Inc.’s (NASDAQ:BIIB) Future? – Yahoo Finance” on May 02, 2019, also Seekingalpha.com with their article: “Biogen’s tofersen shows encouraging action in ALS study – Seeking Alpha” published on May 02, 2019, Nasdaq.com published: “Biogen (BIIB) Dips More Than Broader Markets: What You Should Know – Nasdaq” on April 09, 2019. More interesting news about Biogen Inc. (NASDAQ:BIIB) were released by: Nasdaq.com and their article: “Biogen Earnings: BIIB Stock Slips Despite Q1 Beat – Nasdaq” published on April 24, 2019 as well as Nasdaq.com‘s news article titled: “Biogen (BIIB) Beats on Q1 Earnings, Spinraza Drives Sales – Nasdaq” with publication date: April 24, 2019.

Investors sentiment decreased to 0.91 in Q4 2018. Its down 0.10, from 1.01 in 2018Q3. It dived, as 79 investors sold BIIB shares while 314 reduced holdings. 83 funds opened positions while 276 raised stakes. 181.17 million shares or 8.34% more from 167.21 million shares in 2018Q3 were reported. Peddock Capital Advsr Limited Com holds 2,048 shares or 0.37% of its portfolio. Plancorp Ltd Liability Corp invested in 2,901 shares or 0.4% of the stock. Ajo Ltd Partnership stated it has 0.01% in Biogen Inc. (NASDAQ:BIIB). Tirschwell And Loewy invested in 65,333 shares or 2.98% of the stock. Bancorp Of Hawaii invested in 0.04% or 1,354 shares. Wellington Management Gru Limited Liability Partnership owns 5.40 million shares or 0.41% of their US portfolio. 3,027 were reported by Wright Investors Service. Moreover, Nbt Savings Bank N A has 0.05% invested in Biogen Inc. (NASDAQ:BIIB). Moreover, Intact Invest Mngmt Incorporated has 0.01% invested in Biogen Inc. (NASDAQ:BIIB). West Oak Cap Ltd Llc holds 0% or 4,802 shares in its portfolio. State Of Tennessee Treasury Department stated it has 70,977 shares. 6,753 are owned by Triangle Wealth Mngmt. Teachers Retirement Systems Of The State Of Kentucky reported 106,279 shares stake. Welch & Forbes Llc reported 6,743 shares or 0.06% of all its holdings. Oak Assoc Limited Oh owns 23,918 shares.

Since January 30, 2019, it had 1 buy, and 0 selling transactions for $20.57 million activity. 62,800 shares were bought by DENNER ALEXANDER J, worth $20.57M on Wednesday, January 30.

Microsoft Corporation (NASDAQ:MSFT) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

Westend Advisors Lifted Its Stake in Biogen (BIIB) by $1.05 Billion; As Laredo Petroleum (LPI …

Westend Advisors Llc increased its stake in Biogen Inc. (BIIB) by 3.33% based on its latest 2018Q4 regulatory filing with the SEC. Westend Advisors …

Biogen Inc. (NASDAQ:BIIB) Logo

Westend Advisors Llc increased its stake in Biogen Inc. (BIIB) by 3.33% based on its latest 2018Q4 regulatory filing with the SEC. Westend Advisors Llc bought 3,493 shares as the company’s stock declined 1.50% while stock markets rallied. The institutional investor held 108,238 shares of the biological products (no diagnostic substances) company at the end of 2018Q4, valued at $32.57B, up from 104,745 at the end of the previous reported quarter. Westend Advisors Llc who had been investing in Biogen Inc. for a number of months, seems to be bullish on the $44.55 billion market cap company. The stock decreased 0.33% or $0.75 during the last trading session, reaching $229.78. About 302,695 shares traded. Biogen Inc. (NASDAQ:BIIB) has risen 15.91% since April 29, 2018 and is uptrending. It has outperformed by 11.54% the S&P500. Some Historical BIIB News: 27/03/2018 – ICCR: Shareholders Will Vote on Resolutions at AbbVie, Amgen, Biogen, Bristol-Myers Squibb and Eli Lilly; 05/04/2018 – BIOGEN INC – UNDER TERMS OF AGREEMENT, BIOGEN AND SAMSUNG BIOEPIS WILL MAKE ROYALTY PAYMENTS TO ABBVIE; 24/04/2018 – Biotech Drug Production Pipeline Increasing Amid Buzz of Market Optimism; 10/04/2018 – AveXis sells on Novartis approach; 05/04/2018 – BIOGEN INC – BIOGEN EXPECTS TO LAUNCH IMRALDI IN EUROPE ON OCTOBER 16, 2018; 05/04/2018 – AbbVie in deal with Biogen to delay Humira biosimilar U.S. launch to 2023; 07/03/2018 – Europe’s medicines regulator calls for recall of Biogen, AbbVie multiple sclerosis drug; 24/04/2018 – Biogen Idec 1Q Rev $3.1B; 24/04/2018 – BIOGEN 1Q TECFIDERA REV. $986.9M, EST. $1.01B; 20/04/2018 – Biogen, Ionis Expect to Close Deal in 2Q

Key Group Holdings Cayman Ltd increased its stake in Laredo Petroleum Inc (LPI) by 99.29% based on its latest 2018Q4 regulatory filing with the SEC. Key Group Holdings Cayman Ltd bought 1.67M shares as the company’s stock declined 27.18% while stock markets rallied. The hedge fund held 3.35 million shares of the energy company at the end of 2018Q4, valued at $12.13 million, up from 1.68M at the end of the previous reported quarter. Key Group Holdings Cayman Ltd who had been investing in Laredo Petroleum Inc for a number of months, seems to be bullish on the $741.45M market cap company. The stock decreased 0.79% or $0.025 during the last trading session, reaching $3.155. About 759,672 shares traded. Laredo Petroleum, Inc. (NYSE:LPI) has declined 59.26% since April 29, 2018 and is downtrending. It has underperformed by 63.63% the S&P500. Some Historical LPI News: 26/04/2018 – LPI Capital Bhd 1Q Rev MYR381M; 12/03/2018 – LAREDO PETROLEUM COMMENTS IN SLIDESHOW; 03/04/2018 – Laredo Petroleum Non-Deal Roadshow Set By KLR Group for Apr. 10; 02/04/2018 – Laredo Petroleum Non-Deal Roadshow Set By KLR Group for Apr. 9; 02/05/2018 – LAREDO PETROLEUM 1Q ADJ EPS 24C, EST. 26C; 07/05/2018 – LAREDO PETROLEUM INC LPI.N : KLR GROUP RAISES TARGET PRICE BY $1 TO $12; 26/04/2018 – LPI Capital Bhd 1Q EPS MYR0.2184; 26/04/2018 – LPI CAPITAL 1Q REV. 381.0M RINGGIT; 26/04/2018 – LPI CAPITAL BHD – YEAR-AGO QTRLY REV 347.6 MLN RGT; YEAR-AGO QTRLY NET PROFIT 70.6 MLN RGT; 26/04/2018 – LPI CAPITAL 1Q NET INCOME 72.5M RINGGIT

Since January 30, 2019, it had 1 insider purchase, and 0 selling transactions for $20.57 million activity.

Investors sentiment decreased to 0.91 in Q4 2018. Its down 0.10, from 1.01 in 2018Q3. It turned negative, as 79 investors sold BIIB shares while 314 reduced holdings. 83 funds opened positions while 276 raised stakes. 181.17 million shares or 8.34% more from 167.21 million shares in 2018Q3 were reported. State Treasurer State Of Michigan accumulated 0.33% or 121,077 shares. Amundi Pioneer Asset Mgmt holds 0.14% in Biogen Inc. (NASDAQ:BIIB) or 492,612 shares. Ny State Teachers Retirement Systems reported 0.28% stake. Boston Advisors Ltd Company holds 1,091 shares. Paloma Ptnrs Mgmt Com reported 1,045 shares stake. Tirschwell And Loewy has 65,333 shares. Pictet Asset Management stated it has 0.47% in Biogen Inc. (NASDAQ:BIIB). Regentatlantic Capital owns 4,488 shares for 0.11% of their portfolio. Victory Cap Mngmt accumulated 52,060 shares. Rampart Ltd Co has invested 0.18% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Stearns Group, North Carolina-based fund reported 740 shares. First Retail Bank Of Omaha owns 0.49% invested in Biogen Inc. (NASDAQ:BIIB) for 3,000 shares. Rhenman & Ptnrs Asset Management has invested 2.06% in Biogen Inc. (NASDAQ:BIIB). Fosun Ltd reported 2,000 shares. Chicago Equity Ltd Com holds 13,584 shares.

Westend Advisors Llc, which manages about $932.40B US Long portfolio, decreased its stake in Jpmorgan Chase & Co. (NYSE:JPM) by 15,643 shares to 321,719 shares, valued at $31.41 billion in 2018Q4, according to the filing. It also reduced its holding in Starbucks Corp (NASDAQ:SBUX) by 126,125 shares in the quarter, leaving it with 532,487 shares, and cut its stake in Bristol (NYSE:BMY).

More notable recent Biogen Inc. (NASDAQ:BIIB) news were published by: 247Wallst.com which released: “Short Sellers Can’t Make Up Their Minds on Major Biotechs – 24/7 Wall St.” on April 26, 2019, also Benzinga.com with their article: “Earnings Scheduled For April 24, 2019 – Benzinga” published on April 24, 2019, Nasdaq.com published: “Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report? – Nasdaq” on April 02, 2019. More interesting news about Biogen Inc. (NASDAQ:BIIB) were released by: Nasdaq.com and their article: “Biogen Announces Three New Nominees for Election to Board of Directors – Nasdaq” published on April 29, 2019 as well as Nasdaq.com‘s news article titled: “Why Nightstar Therapeutics Stock Skyrocketed 71% in March – Nasdaq” with publication date: April 03, 2019.

More notable recent Laredo Petroleum, Inc. (NYSE:LPI) news were published by: Benzinga.com which released: “Mid-Afternoon Market Update: Art’s-Way Manufacturing Drops After Q1 Results; Navidea Biopharmaceuticals Shares Climb – Benzinga” on April 08, 2019, also Benzinga.com with their article: “28 Stocks Moving In Tuesday’s Pre-Market Session – Benzinga” published on April 09, 2019, Globenewswire.com published: “Laredo Petroleum Announces Reduction of Personnel Costs by ~25% – GlobeNewswire” on April 08, 2019. More interesting news about Laredo Petroleum, Inc. (NYSE:LPI) were released by: Globenewswire.com and their article: “GATX Corporation Reports 2019 First-Quarter Results NYSE:GATX – GlobeNewswire” published on April 24, 2019 as well as Seekingalpha.com‘s news article titled: “Microcaps dominate midday movers – Seeking Alpha” with publication date: April 08, 2019.

Laredo Petroleum, Inc. (NYSE:LPI) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

Millennium Management LLC Lowers Stake in Ionis Pharmaceuticals Inc (IONS)

Millennium Management LLC trimmed its position in shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 34.9% during the fourth quarter, …

Ionis Pharmaceuticals logoMillennium Management LLC trimmed its position in shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 34.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 83,478 shares of the company’s stock after selling 44,849 shares during the quarter. Millennium Management LLC owned 0.06% of Ionis Pharmaceuticals worth $4,513,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of IONS. Two Sigma Advisers LP raised its position in shares of Ionis Pharmaceuticals by 96.9% during the fourth quarter. Two Sigma Advisers LP now owns 606,911 shares of the company’s stock worth $32,810,000 after purchasing an additional 298,700 shares during the period. D. E. Shaw & Co. Inc. raised its position in shares of Ionis Pharmaceuticals by 252.5% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 410,699 shares of the company’s stock worth $22,202,000 after purchasing an additional 294,184 shares during the period. BlackRock Inc. raised its position in shares of Ionis Pharmaceuticals by 2.9% during the fourth quarter. BlackRock Inc. now owns 7,676,257 shares of the company’s stock worth $414,977,000 after purchasing an additional 213,000 shares during the period. Two Sigma Investments LP raised its position in shares of Ionis Pharmaceuticals by 34.8% during the fourth quarter. Two Sigma Investments LP now owns 727,545 shares of the company’s stock worth $39,331,000 after purchasing an additional 187,876 shares during the period. Finally, Vanguard Group Inc raised its position in shares of Ionis Pharmaceuticals by 1.4% during the third quarter. Vanguard Group Inc now owns 11,091,298 shares of the company’s stock worth $572,089,000 after purchasing an additional 157,770 shares during the period. 85.05% of the stock is currently owned by institutional investors.

In other news, SVP Patrick R. O’neil sold 7,654 shares of the firm’s stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $84.83, for a total transaction of $649,288.82. Following the completion of the sale, the senior vice president now directly owns 27,327 shares of the company’s stock, valued at approximately $2,318,149.41. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Chairman Stanley T. Crooke sold 46,904 shares of the firm’s stock in a transaction on Wednesday, February 13th. The shares were sold at an average price of $60.09, for a total value of $2,818,461.36. Following the sale, the chairman now directly owns 109,634 shares of the company’s stock, valued at $6,587,907.06. The disclosure for this sale can be found here. Insiders sold a total of 339,205 shares of company stock valued at $24,034,607 over the last three months. 2.44% of the stock is currently owned by insiders.

A number of equities analysts have recently weighed in on IONS shares. Zacks Investment Research raised Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $88.00 target price on the stock in a research report on Tuesday, March 26th. TheStreet raised Ionis Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Friday, March 1st. JPMorgan Chase & Co. increased their price target on Ionis Pharmaceuticals from $47.00 to $55.00 and gave the company a “neutral” rating in a research report on Monday, March 18th. BMO Capital Markets increased their price target on Ionis Pharmaceuticals from $70.00 to $82.00 and gave the company an “outperform” rating in a research report on Thursday, February 28th. Finally, ValuEngine raised Ionis Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 28th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $66.33.

NASDAQ IONS opened at $83.28 on Wednesday. The firm has a market capitalization of $11.61 billion, a P/E ratio of 36.00, a P/E/G ratio of 179.74 and a beta of 2.42. Ionis Pharmaceuticals Inc has a 12 month low of $39.07 and a 12 month high of $86.58. The company has a quick ratio of 7.85, a current ratio of 7.88 and a debt-to-equity ratio of 0.53.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings results on Wednesday, February 27th. The company reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $2.46. The business had revenue of $192.00 million during the quarter, compared to analyst estimates of $159.59 million. Ionis Pharmaceuticals had a return on equity of 41.89% and a net margin of 45.64%. Ionis Pharmaceuticals’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.03) EPS. Equities analysts expect that Ionis Pharmaceuticals Inc will post 0.03 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Millennium Management LLC Lowers Stake in Ionis Pharmaceuticals Inc (IONS)” was originally reported by Modern Readers and is the property of of Modern Readers. If you are viewing this story on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this story can be viewed at https://www.modernreaders.com/news/2019/04/17/millennium-management-llc-lowers-stake-in-ionis-pharmaceuticals-inc-ions.html.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Further Reading: Call Option Volume

Want to see what other hedge funds are holding IONS?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals Inc (NASDAQ:IONS).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Actinver Wealth Management Inc. Takes Position in Biogen Inc (BIIB)

AQR Capital Management LLC lifted its position in shares of Biogen by 6.5% during the 3rd quarter. AQR Capital Management LLC now owns …

Biogen logoActinver Wealth Management Inc. purchased a new stake in shares of Biogen Inc (NASDAQ:BIIB) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,425 shares of the biotechnology company’s stock, valued at approximately $387,000.

Several other hedge funds have also recently added to or reduced their stakes in BIIB. BlackRock Inc. increased its holdings in shares of Biogen by 0.4% during the fourth quarter. BlackRock Inc. now owns 16,568,963 shares of the biotechnology company’s stock valued at $4,985,931,000 after acquiring an additional 70,603 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its position in shares of Biogen by 27,620.0% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 14,309,047 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 14,257,427 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Biogen by 6.5% during the 3rd quarter. AQR Capital Management LLC now owns 3,024,037 shares of the biotechnology company’s stock valued at $1,068,422,000 after buying an additional 183,542 shares in the last quarter. Northern Trust Corp lifted its position in shares of Biogen by 4.8% during the 4th quarter. Northern Trust Corp now owns 2,907,306 shares of the biotechnology company’s stock valued at $874,867,000 after buying an additional 133,137 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Biogen by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 2,713,577 shares of the biotechnology company’s stock valued at $815,190,000 after buying an additional 144,464 shares in the last quarter. 89.19% of the stock is owned by institutional investors and hedge funds.

NASDAQ BIIB opened at $240.28 on Thursday. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.32 and a quick ratio of 2.04. The stock has a market capitalization of $46.73 billion, a price-to-earnings ratio of 9.17, a PEG ratio of 0.93 and a beta of 1.04. Biogen Inc has a 1-year low of $216.12 and a 1-year high of $388.67.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Tuesday, January 29th. The biotechnology company reported $6.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.72 by $0.27. The business had revenue of $3.53 billion during the quarter, compared to analysts’ expectations of $3.39 billion. Biogen had a return on equity of 40.53% and a net margin of 32.94%. The business’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter last year, the business posted $5.26 EPS. On average, sell-side analysts forecast that Biogen Inc will post 28.65 earnings per share for the current fiscal year.

In other Biogen news, Director Alexander J. Denner bought 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 30th. The stock was purchased at an average price of $324.86 per share, for a total transaction of $9,745,800.00. Following the completion of the purchase, the director now directly owns 10,909 shares in the company, valued at $3,543,897.74. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Alexander J. Denner bought 7,000 shares of the firm’s stock in a transaction that occurred on Friday, February 1st. The shares were acquired at an average price of $328.45 per share, with a total value of $2,299,150.00. Following the purchase, the director now owns 10,909 shares of the company’s stock, valued at $3,583,061.05. The disclosure for this purchase can be found here. Company insiders own 0.29% of the company’s stock.

A number of brokerages have recently issued reports on BIIB. Canaccord Genuity lowered Biogen from a “buy” rating to a “hold” rating and decreased their target price for the company from $396.00 to $275.00 in a research report on Thursday, March 21st. Wells Fargo & Co lowered Biogen from an “outperform” rating to a “market perform” rating in a report on Thursday, March 21st. JPMorgan Chase & Co. lowered Biogen from an “overweight” rating to a “neutral” rating and set a $244.00 price objective on the stock. in a report on Thursday, March 21st. Raymond James began coverage on Biogen in a report on Wednesday. They issued a “market perform” rating on the stock. Finally, William Blair lowered Biogen from an “outperform” rating to a “market perform” rating in a report on Thursday, March 21st. Two equities research analysts have rated the stock with a sell rating, twenty-two have assigned a hold rating and eight have assigned a buy rating to the company. Biogen presently has an average rating of “Hold” and a consensus price target of $295.04.

COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Modern Readers and is the sole property of of Modern Readers. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.modernreaders.com/news/2019/04/11/1425-shares-in-biogen-inc-biib-purchased-by-actinver-wealth-management-inc.html.

Biogen Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis.

Recommended Story: Technical Analysis of Stocks and What It Means

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Biogen and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts